...ADC in EGFR-mutated NSCLCDaiichi Sankyo Co. Ltd. (Tokyo:4568) presented Phase I data for patritumab deruxtecan (U3-1402...

...Ltd. (Tokyo:4568) presented at the World Conference on Lung Cancer meeting in Barcelona data showing U3-1402...
...Programmed cell death 1; PD-L1 (B7-H1; CD274) - Programmed cell death 1 ligand 1 BioCentury Staff U3-1402 Ocrevus...

...tumors, AML Ph I PLX2853 Bromodomain containing 4 (BRD4) inhibitor AML, solid tumors Ph I U3-1402...
...inhibitor. Among three ADCs that could contribute to its 2025 tally, one has first-in-class potential. U3-1402...
...results presented in October showed that in 42 evaluable HER3-positive breast cancer patients treated with U3-1402...

...Daiichi Sankyo Co. Ltd. (Tokyo:4568) said U3-1402 led to a confirmed overall response rate (ORR) of...
...is available. The preliminary data were from patients who received 1.6-8 mg/kg doses of IV U3-1402...
...breast cancer who have received six or fewer prior chemotherapy regimens to determine a recommended U3-1402...

...U3-1402 every 3 weeks in about 80 patients. A dose-escalation part will evaluate 1.6-9.7 mg/kg U3-1402...
...standard treatment or for whom no standard treatment is available. A dose-finding part will test U3-1402...
...who have received ≤6 prior chemotherapy regimens. Daiichi Sankyo Co. Ltd. (Tokyo:4568), Tokyo, Japan Product: U3-1402...